Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Costanzo FD, Marra F. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. World J Gastroenterol 2014; 20(3): 786-794
Corresponding Author of This Article
Fabio Marra, MD, PhD, Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, Largo Brambilla 3, I-50134 Florence, Italy. email@example.com
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
1Includes 7 patients in whom trans arterial chemio-embolization (TACE) was performed in combination with other treatment modalities, and 2 patients treated with 90Y radio-embolization. HCV: Hepatitis C virus; HBV: Hepatitis B virus; ECOG: Eastern Cooperative Oncology Group; BCLC: Barcelona clinic liver cancer.
Table 2 Incidence of adverse events in 44 patients with cirrhosis and hepatocellular carcinoma undergoing treatment with sorafenib n (%)
1An increase in aminotranspherase and bilirubin after starting sorafenib was observed in all patients;
2Including rash, hypertension, alopecia, diabetes, mucositis, abdominal pain, voice changes. All grades were evaluated according to Common Terminology Criteria for Adverse Event version 3.0. AEs: Adverse events.
Table 3 Changes in laboratory parameters at the beginning and the end of sorafenib treatment according to the reason of treatment interruption
Patients with treatment suspension due to progressive disease (n = 25; median treatment duration 19 wk)
mean (SD) med (min-max)
End of treatment
mean (SD) median (min-max)
Patients with treatment suspension due to AEs (n = 19; median treatment duration 5 wk)
Table 4 Univariate and multivariate analysis of the factors associated with a 16-week “clinical benefit” as defined by the presence of partial response or stable disease at imaging, according to modified Response Evaluation Criteria in Solid Tumors criteria
1Including patients with other concurrent etiologies;
2Removed during the stepwise variable selection, not included in the final multivariate model. AFP: Alpha-fetoprotein; HCV: Hepatitis C virus; HBV: Hepatitis B virus; ECOG: Eastern Cooperative Oncology Group; BCLC: Barcelona clinic liver cancer.
Table 5 Univariate analysis of factors associated with overall survival in 44 patients with hepatocellular carcinoma and cirrhosis treated with sorafenib
Citation: Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Costanzo FD, Marra F. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. World J Gastroenterol 2014; 20(3): 786-794